Ceftazidime/avibactam serum concentration in patients on ECMO
- 28 March 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (5) , 1182-1186
Abstract
The use of extracorporeal membrane oxygenation (ECMO) may alter blood levels of several drugs, including antibiotics, leading to under dosing of these drugs and thus to potential treatment failure. No data exist on pharmacokinetics of new antimicrobial, in particular ceftazidime/avibactam. We therefore perform this study to evaluate ceftazidime/avibactam blood levels in ECMO patients and find factors associated with underdosing. Retrospective observational study of patients on ECMO having received ceftazidime/avibactam and in whom trough blood levels of ceftazidime and avibactam were available. Main outcome measurement was the number of patients with ceftazidime and avibactam blood levels above predefined cut-off values, derived from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa, namely 8 mg/L for ceftazidime and 4 mg/L for avibactam, and explored factors associated with underdosing. Twenty-three ceftazidime/avibactam trough levels were available in 14 ECMO patients, all of them having received veno-venous ECMO for SARS-CoV-2-associated pneumonia. Although ceftazidime levels were above 8 mg/L in all except one patient, nine (39%) of the avibactam dosages were below 4 mg/L. Increased renal clearance (creatinine clearance > 130 mL/min) was the main factor associated with under dosing, since 7 out of the 10 dosages below the predefined cut-offs were measured in patients with this condition. In ECMO patients receiving ceftazidime/avibactam, ceftazidime and avibactam serum levels are above EUCAST breakpoints in most cases, justifying the use of normal dosing in ECMO patients. Increased renal clearance may lead to ceftazidime and avibactam under dosing.Keywords
This publication has 17 references indexed in Scilit:
- Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to runJournal of Antimicrobial Chemotherapy, 2023
- Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections?Antimicrobial Agents and Chemotherapy, 2023
- A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF)Journal of Critical Care, 2023
- Antimicrobial Exposures in Critically Ill Patients Receiving Extracorporeal Membrane OxygenationAmerican Journal of Respiratory and Critical Care Medicine, 2023
- Pharmacokinetics/pharmacodynamics of ceftobiprole in patients on extracorporeal membrane oxygenationInternational Journal of Antimicrobial Agents, 2023
- Ceftazidime/avibactam neurotoxicity in an adult patient with normal renal functionClinical Microbiology and Infection, 2021
- Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#Intensive Care Medicine, 2020
- PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life SupportAnaesthesia Critical Care & Pain Medicine, 2019
- Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance DatabaseJournal of the Neurological Sciences, 2019
- Ex Vivo Model to Decipher the Impact of Extracorporeal Membrane Oxygenation on Beta-lactam Degradation KineticsTherapeutic Drug Monitoring, 2017